How it works

Entyvio is a brand name (trade name) for vedolizumab, a biologic therapy used to treat ulcerative colitis and Crohn's disease.

Entyvio (vedolizumab) binds to the alpha4beta7 integrin on the surface of T-lymphocytes and inhibits its interaction with the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to prevent memory T-lymphocytes (a type of white blood cell) from migrating across the endothelium into inflamed gastrointestinal tract tissue. The interaction of alpha4beta7 integrin with MAdCAM-1 has been identified as a significant contributor to the chronic inflammation seen in ulcerative colitis and Crohn's disease. Simply put, Entyvio reduces the number of white blood cells that enter your GI tract (intestine), which reduces inflammation and the signs and symptoms of Crohn's or ulcerative colitis.

Entyvio is a member of the group of medicines known as integrin receptor antagonists. It can also be referred to as a monoclonal antibody or a selective immunosuppressant.